Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.82 |
| ▸ | HTR2A | P28223 | 3/20 | 0.82 |
| ▸ | HTR1A | P08908 | 2/20 | 0.82 |
| ▸ | HTR1D | P28221 | 2/20 | 0.82 |
| ▸ | HTR1B | P28222 | 2/20 | 0.82 |
| ▸ | HTR2C | P28335 | 2/20 | 0.82 |
| ▸ | HTR2B | P41595 | 2/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | HTR1E | P28566 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
| ▸ | HTR7 | P34969 | 1/20 | 0.82 |
| ▸ | HTR6 | P50406 | 1/20 | 0.82 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
| ▸ | APAF1 | O14727 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599674 | 0.91 | HTR2A (1.00) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL5739268 | 0.91 | HTR2A (1.00) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL274268 | 0.91 | HTR2A (1.00) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL29886359 | 0.91 | HTR2A (1.00) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL8655108 | 0.89 | HTR2A (0.97) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL274201 | 0.89 | HTR2A (0.97) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL30729369 | 0.89 | HTR2A (0.97) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL27539521 | 0.89 | HTR2A (0.97) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL4206927 | 0.87 | HTR2A (0.80) | HTR2AHTR1AHTR1DHTR1BHTR2C | |
| Tryptophan SCHEMBL452982 | 0.87 | KDM4E (0.91) | HTR2AHTR1AHTR1DHTR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| US-20230146925-A1 | DEPOT FORMULATIONS | DURECT CORPORATION (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115804749-A | Injectable controlled release compositions comprising high viscosity liquid carriers | 度瑞公司 | 2023-03-17 | — | — | CN | disclosed |
| CN-115645399-A | Long-acting formulations | 度瑞公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-109602692-B | Injectable controlled release compositions comprising high viscosity liquid carriers | 度瑞公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-109310680-B | Long-acting formulations | 度瑞公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | DURECT CORPORATION (US) | 2022-09-08 | — | — | US | disclosed |
| US-11389202-B2 | Anti-microbial implant | De Puy Synthes Products. Inc. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3999046-A1 | LONG-ACTING FORMULATIONS AND VEHICLES | Durect Corporation (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-0013606-A2 | Drug delivery device and method for its preparation | Key Pharmaceuticals, Inc. (US) | 1980-07-23 | — | — | EP | disclosed |
| US-4178361-A | Sustained release pharmaceutical composition | UNION CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
| US-4136173-A | VEHICLES FOR OPHTHALMIC DRUGS | AMERICAN HOME PRODUCTS CORP. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4034756-A | Osmotically driven fluid dispenser | ALZA CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3996934-A | Medical bandage | ALZA CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3995631-A | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient | ALZA CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3995632-A | Osmotic dispenser | ALZA CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
| US-3962414-A | Structured bioerodible drug delivery device | ALZA CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | ADRA2A 1058/4885HTR2A 2960/4885HTR1A 1528/4885 |
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | HACD3, ACADM, LDHB | ADRA2A 1933/4885HTR2A 711/4885HTR1A 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.